The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Published ·
Keep reading
Loading…
Published ·
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Keep reading
